Galafold (Migalastat)
Pharmacological chaperone for Fabry disease in patients with amenable GLA mutations
Quick Facts About Galafold
Key Takeaways About Galafold
- Only for amenable mutations: Galafold only works for patients whose specific GLA gene mutation has been confirmed as amenable through an in vitro assay – not all Fabry disease patients are eligible
- Unique dosing schedule: Take one 123 mg capsule every other day at the same time, with a 4-hour fasting window (2 hours before and 2 hours after) for optimal absorption
- Cannot combine with ERT: Galafold must not be taken concurrently with enzyme replacement therapy (ERT) such as agalsidase alfa or agalsidase beta
- Regular monitoring required: Your doctor will reassess your condition every 6 months to ensure the treatment remains effective
- First oral treatment for Fabry disease: Galafold was the first non-intravenous therapy approved for Fabry disease, offering convenience over biweekly infusions
What Is Galafold and What Is It Used For?
Galafold (migalastat) is an oral pharmacological chaperone used for the long-term treatment of Fabry disease in adults and adolescents aged 12 years and older who have amenable GLA gene mutations. It stabilizes the body's own defective alpha-galactosidase A enzyme, enabling it to reach the lysosomes and break down accumulated GL-3 substrates.
Fabry disease is a rare, inherited lysosomal storage disorder caused by mutations in the GLA gene, which encodes the enzyme alpha-galactosidase A (α-Gal A). When this enzyme is deficient or dysfunctional, a fatty substance called globotriaosylceramide (GL-3, also known as Gb3) accumulates in cells throughout the body – particularly in the kidneys, heart, and nervous system. This progressive accumulation leads to organ damage and the characteristic symptoms of Fabry disease, including pain episodes, kidney dysfunction, cardiac complications, and stroke.
Galafold contains the active substance migalastat, which works through a fundamentally different mechanism from traditional enzyme replacement therapy (ERT). Rather than supplying an externally produced enzyme through intravenous infusions, migalastat acts as a molecular chaperone. It selectively and reversibly binds to the active site of certain mutant forms of α-Gal A in the endoplasmic reticulum of the cell. This binding stabilizes the enzyme's shape, allowing it to fold correctly and be transported (trafficked) to the lysosomes, where it can carry out its normal function of breaking down GL-3.
The concept of pharmacological chaperone therapy represents a significant advance in the treatment of lysosomal storage disorders. By harnessing the patient's own residual enzyme activity, Galafold offers a targeted approach that does not require the immune system to tolerate an exogenous protein. Clinical trials, including the pivotal ATTRACT study and the FACETS study, demonstrated that migalastat reduced GL-3 levels in kidney tissue, stabilized renal function, and reduced left ventricular mass in patients with amenable GLA mutations over treatment periods of 18 to 24 months.
It is critically important to understand that Galafold does not work for all patients with Fabry disease. The treatment is effective only in patients whose specific GLA mutation produces a protein that can still be stabilized by migalastat. These are called "amenable" mutations. An in vitro assay (the GLP HEK assay) is used to determine whether a patient's mutation responds to migalastat. Currently, over 1,000 GLA mutations have been identified, and approximately 40–50% of disease-causing mutations are considered amenable to Galafold therapy.
Fabry disease affects approximately 1 in 40,000 to 60,000 males, with a milder later-onset phenotype potentially much more common. It is an X-linked condition, meaning males are typically more severely affected, although females can also experience significant symptoms due to random X-chromosome inactivation. Early diagnosis and treatment are crucial for preventing irreversible organ damage.
What Should You Know Before Taking Galafold?
Before starting Galafold, your doctor must confirm that your GLA gene mutation is amenable to migalastat treatment. Do not take Galafold if you are allergic to migalastat or any other ingredients. Galafold must not be used together with enzyme replacement therapy and is not recommended during pregnancy or in patients with severe kidney impairment (GFR below 30 ml/min/1.73 m²).
Contraindications
You must not take Galafold if you have a known allergy (hypersensitivity) to migalastat or any of the other ingredients in the capsule. The other ingredients include pregelatinized starch (corn), magnesium stearate, gelatin, titanium dioxide (E171), and indigo carmine (E132). If you have previously experienced an allergic reaction to any medication containing these components, inform your doctor before starting treatment.
Galafold 123 mg capsules should not be given to children or adolescents (over 12 years) who weigh less than 45 kg, as the dose may not be appropriate for patients with a lower body weight. Additionally, this medication has not been studied in children under 12 years of age, and therefore its safety and efficacy have not been established in that age group.
Warnings and Precautions
Several important precautions should be considered before and during treatment with Galafold:
- Enzyme replacement therapy: If you are currently receiving enzyme replacement therapy (ERT), discuss the transition with your doctor. You must not take Galafold while also receiving ERT, as the two treatments have not been studied in combination and may interfere with each other.
- Regular monitoring: Your doctor will monitor your condition every 6 months while you are on Galafold. This includes assessments of kidney function, cardiac status, and overall disease progression. If your condition worsens, your doctor may perform additional evaluations or discontinue Galafold treatment.
- Severe kidney impairment: Galafold is not recommended in patients with severe renal impairment (glomerular filtration rate < 30 ml/min/1.73 m²), as there is insufficient data on its use in this population.
- Non-amenable mutations: Galafold is only effective for amenable GLA gene mutations. If your mutation is classified as non-amenable, an alternative treatment approach should be considered.
Pregnancy and Breastfeeding
There is very limited experience with the use of Galafold in pregnant women. As a precautionary measure, Galafold is not recommended during pregnancy. Women of childbearing potential who are taking Galafold should use effective contraception throughout their treatment period. If you are pregnant, think you may be pregnant, or are planning to become pregnant, consult your doctor before taking this medication.
It is not known whether migalastat passes into breast milk. If you are breastfeeding, do not take Galafold without first consulting your doctor. Your physician will weigh the benefits of breastfeeding for the infant against the benefits of treatment for the mother to make an appropriate recommendation.
The effects of Galafold on fertility in humans have not been studied. If you are planning to conceive, discuss this with your healthcare provider to ensure appropriate planning around your treatment.
Driving and Operating Machinery
Galafold is unlikely to affect your ability to drive or operate machinery. However, some patients may experience dizziness or fatigue as side effects. If you experience these symptoms, exercise caution when driving or performing activities that require alertness.
How Does Galafold Interact with Other Drugs?
Galafold's most significant interaction is with enzyme replacement therapy (ERT) for Fabry disease – the two must never be used together. Caffeine-containing medications and supplements should be avoided during the fasting period as they may reduce Galafold's effectiveness. Always inform your doctor about all medications you are taking, including over-the-counter products and herbal supplements.
Before starting Galafold, inform your doctor, pharmacist, or nurse about all medications you are currently taking, have recently taken, or might take. This includes prescription drugs, over-the-counter medicines, dietary supplements, and herbal products. Keeping an up-to-date list of all your medications and showing it to your healthcare provider at each visit is strongly recommended.
| Interacting Substance | Type | Effect | Recommendation |
|---|---|---|---|
| Enzyme Replacement Therapy (agalsidase alfa/beta) | Major | Potential interference with mechanism of action | Do not use together. Discuss transition plan with doctor. |
| Caffeine (coffee, tea, energy drinks, supplements) | Moderate | May reduce Galafold absorption during fasting period | Avoid caffeine 2 hours before and 2 hours after taking Galafold |
| Caffeine-containing medications (e.g., analgesic combinations) | Moderate | May reduce Galafold effectiveness during fasting window | Schedule caffeine-containing medications outside the fasting period |
| Food (all types) | Moderate | Reduces absorption of migalastat | Take on empty stomach with 4-hour fasting window |
Migalastat is not known to significantly affect the cytochrome P450 enzyme system, which means major pharmacokinetic drug interactions with common medications are considered unlikely. However, because clinical experience with co-administered drugs is limited, it is always prudent to inform your healthcare team of any changes to your medication regimen.
Caffeine may interfere with Galafold's effectiveness when taken during the fasting period. This includes caffeine from coffee, tea, cola, chocolate, energy drinks, and caffeine-containing medications or supplements. Plain water, flavored or sweetened water, pulp-free fruit juices, and caffeine-free carbonated beverages are safe to consume during the 4-hour fasting window.
What Is the Correct Dosage of Galafold?
The recommended dose of Galafold is one 123 mg capsule taken orally every other day at the same time of day. Do not eat food or consume caffeine for at least 2 hours before and 2 hours after taking the dose. A total fasting period of at least 4 hours is required for proper absorption. Swallow the capsule whole – do not split, crush, or chew it.
Always take Galafold exactly as directed by your doctor, pharmacist, or nurse. If you are unsure about any aspect of your dosing schedule, ask your healthcare provider for clarification. The fixed dose of 123 mg every other day applies to all eligible patients regardless of body weight (for patients weighing 45 kg or more), making the dosing straightforward.
Adults and Adolescents (12 years and older, ≥45 kg)
Standard Dosage
Dose: 123 mg (one capsule) orally
Frequency: Every other day, at the same time of day
Important: Do not take on two consecutive days
Fasting: No food or caffeine for 2 hours before and 2 hours after dosing (minimum 4-hour total fasting window)
Administration: Swallow capsule whole with water. Do not split, crush, or chew.
The every-other-day dosing schedule is integral to how Galafold works. Migalastat acts as a pharmacological chaperone by binding to the mutant α-Gal A enzyme, stabilizing it and facilitating its transport to the lysosomes. The alternating-day schedule allows the chaperone to dissociate from the enzyme in the lysosomes on the off-days, freeing the enzyme to perform its catalytic function of breaking down GL-3. Taking Galafold on consecutive days could result in the enzyme remaining bound to the chaperone for too long, potentially reducing its ability to metabolize GL-3.
Children Under 12 Years
Galafold has not been studied in children under 12 years of age. Therefore, the safety and efficacy of this medication have not been established for this age group. Treatment decisions for children under 12 with Fabry disease should be made by a specialist experienced in managing lysosomal storage disorders.
Elderly Patients
No dose adjustment is required for elderly patients. The standard dose of 123 mg every other day applies to older adults as well. However, elderly patients with Fabry disease may have more advanced organ involvement, and close monitoring of kidney function and cardiac status is particularly important in this population.
Missed Dose
If you forget to take your capsule at the usual time but remember later the same day, you may take the dose as long as no more than 12 hours have passed since the scheduled dosing time. If more than 12 hours have elapsed, skip the missed dose entirely and resume your regular dosing schedule on the next planned dosing day. Do not take two capsules to compensate for a missed dose.
Overdose
If you take too many capsules, stop taking the medication and contact your doctor immediately. Symptoms of overdose may include headache and dizziness. There is no specific antidote for migalastat overdose, and treatment is supportive based on the symptoms experienced.
Do not discontinue Galafold without first discussing it with your doctor. Stopping treatment abruptly could lead to a recurrence of GL-3 accumulation and worsening of Fabry disease symptoms. If you have any concerns about your treatment, speak with your healthcare provider.
What Are the Side Effects of Galafold?
The most common side effect of Galafold is headache, affecting more than 1 in 10 patients. Common side effects include palpitations, diarrhea, nausea, abdominal pain, constipation, dry mouth, fatigue, muscle cramps, dizziness, rash, and weight gain. Uncommon side effects include angioedema (sudden swelling of skin or mucous membranes). Most side effects are mild to moderate.
Like all medicines, Galafold can cause side effects, although not everyone experiences them. The safety profile of migalastat has been established through clinical trials involving patients with Fabry disease treated for up to several years. Below is a comprehensive overview of reported side effects organized by frequency.
Very Common
- Headache
Common
- Palpitations (sensation of heartbeat)
- Vertigo (spinning sensation)
- Diarrhea
- Nausea
- Abdominal pain
- Constipation
- Dry mouth
- Sudden urge to defecate
- Indigestion (dyspepsia)
- Fatigue
- Elevated creatine phosphokinase levels (blood test)
- Weight gain
- Muscle cramps
- Muscle pain (myalgia)
- Painful stiff neck (torticollis)
- Tingling in extremities (paresthesia)
- Dizziness
- Decreased sensitivity to touch (hypoesthesia)
- Depression
- Protein in urine (proteinuria)
- Shortness of breath (dyspnea)
- Nosebleeds (epistaxis)
- Rash
- Persistent itching (pruritus)
- Pain
Uncommon
- Angioedema (sudden swelling of the skin or mucous membranes, e.g., lips, tongue, eyes)
Elevated creatine phosphokinase (CPK) levels are a relatively frequent finding in patients treated with Galafold and are typically detected through routine blood tests. In most cases, these elevations are transient and asymptomatic. However, if you experience unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever or malaise, contact your doctor as this could indicate a more significant muscle-related issue.
Proteinuria (protein in the urine) has been reported in some patients. This finding requires careful interpretation, as proteinuria is also a hallmark of Fabry disease-related kidney involvement. Your doctor will distinguish between disease progression and medication-related effects through regular monitoring.
It is important to report suspected side effects after a medicine has been authorized. This enables ongoing monitoring of the medicine's benefit-risk balance. Healthcare professionals and patients are encouraged to report any suspected adverse reactions to their national medicines regulatory authority (e.g., FDA MedWatch in the US, Yellow Card Scheme in the UK, or EMA EudraVigilance in the EU).
How Should You Store Galafold?
Store Galafold out of the sight and reach of children. No special temperature requirements apply, but keep the capsules in the original packaging to protect from moisture. Do not use the capsules after the expiry date printed on the carton and blister pack.
Proper storage of medications is essential to maintain their effectiveness and safety. Follow these guidelines for Galafold:
- Temperature: No special temperature storage conditions are required. Store at normal room temperature.
- Moisture protection: Keep the capsules in the original blister packaging to protect against moisture.
- Child safety: Store out of the sight and reach of children at all times.
- Expiry date: Do not use after the expiry date (EXP) printed on the carton and blister pack. The expiry date refers to the last day of the stated month.
- Disposal: Do not dispose of medicines via wastewater or household waste. Ask your pharmacist how to properly dispose of medicines that are no longer needed to help protect the environment.
Each Galafold blister card contains 14 capsules, representing 28 days of treatment (since the medication is taken every other day). The blister card also includes 14 white cardboard circles that serve as reminders for the days when you do not take the medication. This innovative packaging design helps patients adhere to the alternating-day dosing schedule.
What Does Galafold Contain?
Each Galafold capsule contains migalastat hydrochloride equivalent to 123 mg of migalastat as the active ingredient. The capsules are opaque, blue and white, size 2, marked with "A1001" in black ink, containing white to light brown powder.
Understanding the full composition of your medication can be important, particularly if you have known allergies to specific excipients or colorants.
Active Ingredient
Each hard capsule contains migalastat hydrochloride, equivalent to 123 mg of migalastat (the active moiety). Migalastat hydrochloride is a synthetic iminosugar that acts as a pharmacological chaperone for the alpha-galactosidase A enzyme.
Inactive Ingredients (Excipients)
- Capsule contents: Pregelatinized starch (corn) and magnesium stearate
- Capsule shell: Gelatin, titanium dioxide (E171), and indigo carmine (E132)
- Printing ink: Shellac, black iron oxide, and potassium hydroxide
Physical Description
Galafold capsules are opaque, blue and white hard capsules (size 2, measuring 6.4 × 18.0 mm) printed with "A1001" in black ink. The capsules contain white to light brown powder. They are supplied in blister packs containing 14 capsules per card.
Marketing Authorization Holder
Galafold is developed and marketed by Amicus Therapeutics Europe Limited, based in Dublin, Ireland. The medication is manufactured by Almac Pharma Services (Ireland) Limited in Dundalk, Ireland. For additional information about Galafold, consult the European Medicines Agency (EMA) website, which provides detailed information including the full summary of product characteristics and links to resources about rare diseases and their treatments.
Frequently Asked Questions About Galafold
Galafold (migalastat) is used for the long-term treatment of Fabry disease in adults and adolescents aged 12 years and older who have certain amenable mutations in the GLA gene. Fabry disease is a rare genetic disorder where a defective enzyme leads to accumulation of a fatty substance (GL-3) in organs including the kidneys, heart, and nervous system. Galafold works by stabilizing the patient's own defective enzyme, helping it function more effectively.
Take one 123 mg capsule every other day at the same time of day. You must fast for at least 2 hours before and 2 hours after taking the capsule (no food or caffeine). Water, pulp-free fruit juices, and caffeine-free drinks are allowed during fasting. Swallow the capsule whole – never split, crush, or chew it. The blister pack includes reminder circles for off-days.
The most common side effect is headache (affecting more than 1 in 10 people). Other common side effects include palpitations, diarrhea, nausea, stomach pain, constipation, dry mouth, fatigue, muscle cramps, muscle pain, dizziness, tingling sensations, rash, itching, and weight gain. Most side effects are mild to moderate in severity. Contact your doctor if side effects become bothersome or persistent.
No, you must not take Galafold at the same time as enzyme replacement therapy. If you are currently on ERT, your doctor will create a transition plan for switching to Galafold. The two treatments work through different mechanisms and have not been studied together. Never combine them without explicit medical guidance.
No. Galafold only works for patients with specific "amenable" GLA gene mutations that produce an enzyme capable of being stabilized by migalastat. Your doctor will use genetic testing and an in vitro assay to determine if your particular mutation is amenable. Approximately 40–50% of known disease-causing GLA mutations are considered amenable. Patients with non-amenable mutations need alternative treatments such as enzyme replacement therapy.
If you miss your dose but remember within 12 hours of your usual dosing time, take the capsule right away. If more than 12 hours have passed, skip the missed dose and take your next scheduled dose on the correct day. Never take two capsules to make up for a missed dose. Continue following your every-other-day schedule from the next dosing day.
References
All information in this article is based on the following peer-reviewed sources and international medical guidelines:
- European Medicines Agency (EMA). Galafold (migalastat) – Summary of Product Characteristics. Last updated 2025. Available at: ema.europa.eu
- Hughes DA, Nicholls K, Shankar SP, et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet. 2017;54(4):288–296. doi:10.1136/jmedgenet-2016-104178
- Germain DP, Hughes DA, Nicholls K, et al. Treatment of Fabry's disease with the pharmacologic chaperone migalastat. N Engl J Med. 2016;375(6):545–555. doi:10.1056/NEJMoa1510198
- Feldt-Rasmussen U, Hughes DA, Sunder-Plassmann G, et al. Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study. Mol Genet Metab. 2020;131(1–2):219–228.
- U.S. Food and Drug Administration (FDA). Galafold (migalastat) capsules, for oral use – Prescribing Information. Revised 2024.
- Ortiz A, Germain DP, Desnick RJ, et al. Fabry disease revisited: Management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123(4):416–427.
- World Health Organization (WHO). Lysosomal storage disorders – Essential diagnostics list. 2023.
- Benjamin ER, Flanagan JJ, Schilling A, et al. The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines. J Inherit Metab Dis. 2009;32(3):424–440.
About the Medical Editorial Team
This article was written and medically reviewed by the iMedic Medical Editorial Team, consisting of licensed physicians and pharmacologists with expertise in rare diseases and metabolic disorders. All content follows international evidence-based guidelines (EMA, FDA, WHO) and the GRADE framework for evaluating evidence quality.
All medical information is reviewed by board-certified physicians specializing in metabolic diseases and clinical pharmacology. Content is verified against current EMA and FDA prescribing information.
Evidence Level 1A based on systematic reviews and randomized controlled trials. All sources are peer-reviewed and from internationally recognized medical organizations.